M&A Deal Summary |
|
|---|---|
| Date | 2024-10-14 |
| Target | Gynesonics |
| Sector | Medical Products |
| Buyer(s) | Hologic |
| Sellers(s) | HBM Partners |
| Deal Type | Add-on Acquisition |
| Deal Value | 350M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1985 |
| Sector | Medical Products |
| Revenue | 4.0B USD (2024) |
Hologic is a developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products, with an emphasis on serving the healthcare needs of women throughout the world. Hologic was formed in 1985 and is based in Marlborough, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 25 of 25 |
| Sector: Medical Products M&A | 19 of 19 |
| Type: Add-on Acquisition M&A Deals | 23 of 23 |
| State: California M&A | 5 of 5 |
| Country: United States M&A | 18 of 18 |
| Year: 2024 M&A | 2 of 2 |
| Size (of disclosed) | 6 of 24 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-04-29 |
Endomagnetics
Cambridge, United Kingdom Endomagnetics develops and sells breast surgery localization and lymphatic tracking technologies. Endomagnetics is based in Cambridge, United Kingdom. |
Buy | $310M |
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 2.1B USD |
| Size | Large |
| Type | Sector Focused |
HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 36 of 40 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 6 of 7 |
| State: California M&A | 9 of 9 |
| Country: United States M&A | 27 of 27 |
| Year: 2024 M&A | 3 of 4 |
| Size (of disclosed) | 4 of 5 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-10-14 |
Longboard Pharmaceuticals
La Jolla, California, United States Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals was founded in 2020 and is based in La Jolla, California. |
Sell | $2.6B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-12-18 |
Sai Life
Hyderabad, India Sai Life is an integrated provider of drug discovery, development, and manufacturing solutions for innovator pharmaceutical and biotechnology companies. The company’s ongoing commitment to quality, thorough approach, and state-of-the-art research and manufacturing facilities enable its highly skilled team of professionals to provide its clients with competitive advantages such as shorter time to market and risk minimization. Sai Life was founded in 1999 and is based in Hyderabad, Telangana. |
Sell | - |
